Abstract. The effects of neuromedin B (NMB), gastrin-releasing peptide (GRP)-10 and their C-terminal fragment peptides on the pancreatic and gastrointestinal hormone release were studied in dogs. Intravenous bolus injections of NMB and GRP-10 (4.5 nmol/kg) into conscious dogs elicited a sharp and statistically significant rise in plasma gastrin and insulin levels, but only GRP-10 brought on a significant rise in the plasma glucagon and enteroglucagon levels. The degree of stimulation of gastrin and insulin secretion by NMB and GRP-10 was dose-dependent. With a dose of 4.5 nmol/kg, the minimum size of C-terminal fragment peptides of NMB and GRP-10 to stimulate gastrin secretion was NMB (2–10) and GRP-10 (3–10), respectively. Both NMB and GRP-10 (0.1-100 nmol/l) stimulated insulin release from the isolated canine pancreas. The glucagon release was stimulated by 10 and 100 nmol/l GRP-10 and was not stimulated by the same doses of NMB. The somatostatin release was not influenced by either peptide. It is concluded that 1) NMB and GRP-10 can stimulate gastrin and pancreatic hormone secretion, and the latter effect may be mainly due to a direct action on the islet cells; 2) the stimulatory effect of GRP-10 is stronger than that of NMB. The difference in the minimal active fragment between NMB and GRP-10 suggests that the amino acid of position 3 – NMB (Leu) and GRP-10 (His) – may play an important role in their biological activity.
The effects of substance P (SP) and SP-(6-11) (SP6-11) on hormone secretion from the isolated perfused pancreas were compared in rats and dogs under the same conditions. In the rat, SP inhibited insulin secretion in a dose-dependent manner in a concentration range of 0.1-10 nM. Glucagon secretion was inhibited at a minimal dose of 10 nM SP. No significant effect on somatostatin secretion was obtained. SP6-11 exhibited the identical inhibitory potency as SP on both insulin and glucagon release from the rat pancreas. In the canine pancreas, by contrast, 1 and 10 nM SP and SP6-11, respectively, potentiated the release of insulin, glucagon, and somatostatin. Potentiation by SP6-11 was less than that by SP. These results demonstrate species differences in the effects of SP and SP6-11 on the release of pancreatic hormones.
The present experiment was carried out to investigate the metabolism of palatinose (6-O-alpha-D-glucopyranosyl-D-fructose) in the rat. The bolus injection of palatinose (0.5 g/kg) in the tail vein of normal and streptozotocin (STZ) diabetic rats caused significant increments in glucose and insulin concentrations. However, in severe STZ diabetic rats (greater than 300 mg/dl of fasting plasma glucose) no significant change in glucose and insulin concentrations was observed. In liver perfusion, the gradual decrease in glucose output from the normal and mild STZ diabetic rat livers perfused with 20 mM Krebs-Ringer-Tris buffer pH 7.4 was prevented by the addition of 5.5 mM palatinose in the perfusate and fructose was detected in the effluent during the palatinose infusion. The results indicate that palatinose is metabolized to glucose and fructose in both normal and diabetic rat tissues, and this causes the increase in blood glucose concentration. On the other hand, the direct stimulatory effect of insulin release from pancreatic B-cell was not observed when the palatinose was infused into the isolated perfused rat pancreas. The study suggest that palatinose administered parenterally is metabolized by tissues and expected to be used as a source of fluid and energy supply.
Directional blood flow in pancreatic islets may be important for regulation of islet hormone release. We therefore perfused an isolated canine pancreas via the celiac artery (arterial perfusion) and then via the portal vein (venous perfusion) in the same pancreas. Basal insulin and glucagon levels and their rate of release in response to 10 mM arginine, 11 mM glucose, 500 pg/ml somatostatin, or 500 pg/ml glucagon were similar under both conditions. However, the inhibition of glucagon release due to somatostatin and its recovery after the cessation of somatostatin infusion was poor in the case of venous perfusion. The basal somatostatin level and its release in response to 10 mM arginine, 11 mM glucose, and 500 pg/ml glucagon during venous perfusion was significantly higher than that during arterial perfusion. From these results, it is speculated that the directional blood flow in pancreatic islets may not be essential for regulation of hormone release from the canine pancreas or that such directionality does not exist in canine pancreatic islets, and that a considerable portion of released somatostatin may be taken up by the pancreas located downstream--probably in the exocrine pancreas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.